Investor Overview

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions.

We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology clinical programs.

Stock Quote

Recent News

Toggle Summary Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress
Primary axillary hyperhidrosis is a medical condition that can occur in the pediatric population and is largely undertreated and under-diagnosed Post-hoc analysis of ARIDO long-term safety study demonstrated reduced sweat production, and improved disease severity and quality of life, relative to
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis
Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx Company announces DermiraConnect, a new patient access program that will provide patients broad access to QBREXZA Therapy is expected to be available in pharmacies nationwide beginning October 1, 2018 MENLO
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update 
- QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 - QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 - Lebrikizumab Phase 2b enrollment expected to be completed by end of 2018 MENLO PARK, Calif. , Aug.

Upcoming Events

There are currently no events to display.

Copyright West LLC. Minimum 15 minutes delayed.